Invictus Pharmacy now accepts Ethereum, Solana, and XRP at all retail locations, with online payments coming Jan 1, 2026. Its parent company is building a blockchain payment rail for the U.S. prescription drug market.
MicroT Biotech has raised over $50 million in Series A and A+ funding to advance GT801, a CD19-targeting in vivo CAR-T candidate. The deal highlights rising institutional confidence in in vivo CAR-T as the field moves from concept to parallel financing, clinical, and industrial validation.
MicroT Biotech has raised over $50 million in Series A and A+ financing to advance GT801, its CD19-targeting in vivo CAR-T candidate. The deal highlights growing institutional interest in scalable cell therapy platforms amid rising global M&A activity in the in vivo CAR-T space.
Azeem Ahmed, founder of Mochi Finance, sold 550,285 CVX for $946K, causing a 10% price drop. He faces allegations of diverting over $54M in DeFi funds via Curve pool exploit and governance attacks.
Mochi Finance founder Azeem Ahmed sold 550,285 CVX tokens for approximately $946,000, triggering a 10% CVX price drop. The tokens originated from a 2021 Curve pool attack causing over $54 million in losses. Investigations reveal diverted rewards exceeding $8 million, facing SEC and FBI probes.
Mochi Finance founder Azeem Ahmed sold 550,000 CVX for $946K, causing a 10% price drop. The tokens originated from a 2021 Curve pool drain causing over $54M in losses. He faces fraud allegations across multiple DeFi projects, with diverted rewards exceeding $8M. The sale signals potential further liquidation.
Mochi Finance founder Azeem Ahmed sold 550,285 CVX tokens for ~$946,000, triggering a 10% price drop. On-chain probes link the funds to a 2021 Curve pool drain and allege over $54M in total losses across multiple projects, with potential SEC and RICO charges.
Mochi Finance founder Azeem Ahmed sold 550,285 CVX for ~$946K, triggering a 10%+ drop. The tokens originate from a 2021 Curve pool exploit linked to $54M in losses. He faces fraud claims across four DeFi projects, with further sales posing liquidity risks to CVX.
